 |
Top 6 Startups developing new antibiotics
Updated: May 06, 2024 | Editor: Jason Kwon |
These startups are pioneering the discovery and development of innovative technologies, such as next-generation sequencing, machine learning algorithms, and synthetic biology approaches, to combat antibiotic resistance and address the urgent need for novel antimicrobial agents.
1
Country: USA | Funding: $443.6M
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
2
Country: Netherlands | Funding: €96.1M
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
Micreos is a developer of phage technology for targeted control of bacteria. Micreos’ big idea is to use enzymes made by bacteriophages to selectively take out bacteria without drug resistance.
3
Country: USA | Funding: $81.7M
Aridis is a biopharmaceutical company focused on the development of human antibodies for hospital-related infections
Aridis is a biopharmaceutical company focused on the development of human antibodies for hospital-related infections
4
Country: USA | Funding: $147.3K
NovoBiotic Pharmaceuticals is a biotechnology company focused on the discovery and development of new drugs from natural sources.
NovoBiotic Pharmaceuticals is a biotechnology company focused on the discovery and development of new drugs from natural sources.
5
Country: Australia | Funding: $2.5M
Botanix Pharmaceuticals intends to improve the lives of patients suffering from serious skin diseases including acne, psoriasis and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.
Botanix Pharmaceuticals intends to improve the lives of patients suffering from serious skin diseases including acne, psoriasis and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.
6
Country: Switzerland | Funding: €71.4K
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
